Skip Navigation



Rheumatology Advance Access published online on January 31, 2006
Rheumatology, doi:10.1093/rheumatology/kei253
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
45/6/765    most recent
kei253v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Shen, H.
Right arrow Articles by Sprott, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shen, H.
Right arrow Articles by Sprott, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Received July 13, 2005
Accepted November 11, 2005

Original Papers

Analgesic action of acetaminophen in symptomatic osteoarthritis of the knee

H. Shen 1, H. Sprott 1, A. Aeschlimann 2, R. E. Gay 1, B. A. Michel 1, S. Gay 1, and H. Sprott 1 *

1 Center of Experimental Rheumatology, Department of Rheumatology and Institute of Physical Medicine, University Hospital, Zürich; Center for Integrative Human Physiology (CIHP), University of Zürich, Zürich
2 RehaClinic, Zurzach, Switzerland

* To whom correspondence should be addressed.
H. Sprott, E-mail: haiko.sprott{at}usz.ch


  Abstract

Objectives. The study was designed to investigate the analgesic effects and mechanisms of acetaminophen (paracetamol) in symptomatic osteoarthritis (OA) of the knee.

Methods. Twenty patients with symptomatic OA were randomly allocated to two groups treated with either acetaminophen or rofecoxib for 3 months. Visits and measurements were scheduled upon entry (T0), at month 1 (T1) and at month 3 (T3). The intensity of joint pain was evaluated with a 100-mm visual analogue scale (VAS). The physical function of the affected knee was evaluated with a questionnaire comparable to the Western Ontario McMaster Universities Osteoarthritis Index (WOMAC). Levels of serotonin, substance P (SP) and {beta}-endorphin (BEND) were determined with commercial enzyme-linked immunoassay kits. The expression of {kappa} opioid receptor (KOR) in peripheral mononuclear blood cells (PBMCs) was quantified by real-time PCR.

Results. Both acetaminophen and rofecoxib relieved pain considerably but with different kinetics, and affected different biomarkers. Rofecoxib appeared to be more efficient, reducing pain intensity by 56% at T1 (P<0.01), whereas acetaminophen reduced it by only 29%. Physical function improved in both groups by T3. Correlated with the pain relief, acetaminophen significantly reduced plasma BEND levels, whereas rofecoxib did not do so. In both groups plasma SP levels were elevated compared with T0. A reduction in serum serotonin was detected in the rofecoxib group at T1 (P=0.004) but had recovered at T3. No changes in KOR mRNA in PBMCs were observed in either group.

Conclusions. There is a correlation between reduction in circulating BEND and OA pain relief in patients treated with acetaminophen.

Keywords: Acetaminophen; Beta-endorphin; Osteoarthritis; Pain; Rofecoxib..
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.